Case 2 – Adjuvant therapy in a patient with HER2-positive early breast carcinoma
AbstractApproximately 20% of breast cancer patients harbor tumors that overexpress human epidermal growth factor receptor 2 (HER2), which represents an adverse prognostic factor. The therapeutic landscape for this type of breast cancer has been transformed by the approval of anti-HER2 agents for adjuvant and neoadjuvant settings. Despite that, some of these patients will eventually relapse. Dual HER2 blockade has been successfully tried in early and advanced breast cancer. Here we report the case of an early HER2-positive breast cancer patient treated with trastuzumab, pertuzumab, and chemotherapy. The recently released final results of the much anticipated APHINITY trial confirm the outcome achieved in this patient.
Copyright (c) 2017 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.